Comparison of teicoplanin and vancomycin in initial empirical antibiotic regimen for febrile neutropenic patients
Latest Information Update: 07 Jun 2009
Price :
$35 *
At a glance
- Drugs Teicoplanin (Primary) ; Vancomycin
- Indications Febrile neutropenia; Gram-positive infections
- Focus Therapeutic Use
- Sponsors Sanofi
- 18 May 2009 Primary endpoint 'Clinical response' has been met.
- 18 May 2009 Results have been reported at 19th European Congress of Clinical Microbiology and Infectious Diseases.
- 15 Sep 2008 sanofi-aventis reported as trial affiliate by ClinicalTrials.gov.